Graeme has more than 25 years’ experience in oncology research, with significant expertise and in-depth knowledge in the field of DDR.
He joins Artios from AstraZeneca, where he held the position of Senior Director of Bioscience within the Oncology Innovative Medicines and Early Development (IMED) division. In this role, Graeme was responsible for leading a group of approximately 100 bioscientists in target validation and the discovery and development of novel anti-cancer agents. Prior to joining AstraZeneca, he was Head and Research Director at KuDOS Pharmaceuticals where he played a key role in the discovery and development of Lynparza™ (olaparib), the first targeted DDR inhibitor to reach the market.
Graeme gained his PhD from the University of Edinburgh and subsequently worked as a Research Fellow at the Wellcome/CRC Institute at the University of Cambridge in the laboratory of Professor Steve Jackson, FRS.